Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

WHO OKs New Genome Editing Registry, Calls For Governance Framework

Executive Summary

A new global registry is being set up to log all research involving genome editing, and there are plans for an online consultation on a governance framework on such research. The Alliance for Regenerative Medicine has welcomed the fact that the new registry will not be as burdensome for therapeutic developers as it originally thought.

You may also be interested in...



WHO's Human Genome Editing Standards Must Not Impact Somatic Cell Research

Concerns have been expressed that efforts by the World Health Organization to establish global standards for the whole spectrum of human genome editing research may inadvertently have a negative impact on companies developing somatic cell therapy medicinal products.

Hungary Breaks Ranks With EU & Authorizes Use Of AstraZeneca Vaccine

Hungary is going its own way when it comes to coronavirus vaccines, but its decision to allow the emergency use of the Oxford University/AstraZeneca vaccine may be only a symbolic expression of the government’s growing impatience with the EU.

Valneva Starts COVID-19 Vaccine Production In Scotland

Valneva is scaling up manufacture of its coronavirus vaccine alongside the clinical development program, with a view to meeting its commitment to provide millions of doses for use in the UK and the EU.

Topics

UsernamePublicRestriction

Register

LL029263

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel